[ <sup>111</sup> In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-Arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy
Stefan Pool(Erasmus MC), Casper H.J. van Eijck(Erasmus MC), Gerben A. Koning(Università Cattolica del Sacro Cuore), Boen L.R. Kam(Erasmus MC), Mark Konijnenberg(Mallinckrodt (Ireland)), Woulter A.P. Breeman(Erasmus MC), Timo L.M. ten Hagen(Erasmus MC), Eric P. Krenning(Cyclotron (Netherlands)), Marion de Jong(Shell (Netherlands))
Cited by 28
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914